| Literature DB >> 31662760 |
Roman Labuda1,2, Andreas Bernreiter2,3, Doris Hochenauer3, Christoph Schüller2,3, Alena Kubátová4, Joseph Strauss2,3, Martin Wagner1,2.
Abstract
A new species, Saksenaea dorisiae (Mucoromycotina, Mucorales), isolated from a water sample originating from a private well in Manastirica, Petrovac, in the Republic of Serbia (Europe), is described and illustrated. The new taxon is well supported by multilocus phylogenetic analysis that included the internal transcribed spacer (ITS) region, domains D1 and D2 of the 28S rRNA gene (LSU), and translation elongation factor-1α gene (tef-1α), and it is resolved in a clade with S. oblongispora and S. trapezispora. This fungus is characterized by its moderately slow growth at 15 and 37°C, sparse rhizoids, conical-shaped sporangia, and short-cylindrical sporangiospores. Saksenaea dorisiae is a member of the opportunistic pathogenic genus often involved in severe human and animal mucormycoses encountered in tropical and subtropical regions. Despite its sensitivity to several conventional antifungals (terbinafine and ciclopirox), the fungus can potentially evoke clinically challenging infections. This is the first novel taxon of the genus Saksenaea described from the moderately continental climate area of Europe.Entities:
Year: 2019 PMID: 31662760 PMCID: PMC6778886 DOI: 10.1155/2019/6253829
Source DB: PubMed Journal: Int J Microbiol
List of strains included in the study.
| Strain | Source | GenBank accession no. | ||
|---|---|---|---|---|
| ITS | Tef-1 | D1/D2 domains of 28S rRNA gene (LSU) | ||
|
| Water from a private well, the Republic of Serbia |
|
|
|
|
| Cutaneous lesion, Tarragona, Spain | FR687326 | HM776689 | HM776678 |
|
| Skin lesions, France | FR687325 | HM776688 | HM776677 |
|
| Soil, India | FR687327 | HM776690 | AF113483 |
|
| Human tissue, USA | FR687329 | HM776692 | HM776681 |
|
| Human tissue, USA | FR687332 | HM776695 | HM776684 |
|
| Craniofacial tissue and brain, USA | FR687322 | HM776685 | HM776674 |
|
| Palate necrotic tissue, India | LT796164 | LT796166 | LT796165 |
|
| Eye, USA | FR687330 | HM776693 | HM776682 |
|
| Bovine fetus, USA | NR 149333 | HM776691 | NG 059935 |
|
| Blood, Middle East | FR687331 | HJN206536M776694 | HM776683 |
|
| Forest soil, Brazil | JN206283 | HM776687 | NG 057868 |
|
| Knee wound, USA | NR 147690 | LT607408 | NG 060019 |
|
| Soil, India | NR 149336 | AF157231 | JN206536 |
FMR, Facultat de Medicina in Ciències de la Salut, Reus, Spain; CNRMA, Centre National de Référence Mycologie et Antifongiques, Paris, France; NRRL, ARS culture collection, Peoria, IL, USA; UTHSC, Fungus testing laboratory, University of Texas Health Sciences Center, San Antonio, TX, USA; ATCC, American Type Culture Collection, Manassas, VA, USA; M-1012/15 = FMR 14516; CBS, Westerdijk Fungal Biodiversity Centre, Utrecht, the Netherlands; BiMM, Bioactive Microbial Metabolites unit, UFT-Tulln, Austria; ex-type strain. Newly obtained data are in bold.
Figure 1Maximum Likelihood tree based on a concatenated set of 3 sequences (ITS, LSU, and tef-1α) for the new taxon S. dorisiae is compared with species from the same genus Saksenaea. Numbers at nodes indicate bootstrap values (expressed as percentages of 1000 replications). Apophysomyces elegans CBS 476.78 was used as an outgroup. Scale bar indicates 0.02 substitutions per nucleotide position. S = Saksenaea, A = Apophysomyces; ex-type strain. New species is in bold.
Figure 2Saksenaea dorisiae (BiMM-F232). Colonies on CZA and MEA (4 days old) at 35 (a) and 37°C (b).
Figure 3Saksenaea dorisiae (BiMM-F232). (a)–(e) Sporangiophores with sporangia (on CZA, 6 days old). (f)–(h) Young sporangia with rounded neck (closed). (i) Details of asperulate sporangiophore (on CZA, 6 days old). (j)–(l) Sporangiospores and details of sporangial neck (on CZA, 6 days old). Scale bars = 500 μm (a), 50 μm (b)–(g), 10 μm (h)–(l).
Figure 4Line drawing of micromorphology of Saksenaea dorisiae (BiMM-F232). (a, b, and c) sporangiophores, sporangia, and sporangiospores on CZA (6–8 days old). (a) Sporangiophores with sporangium and mature sporangiospores. (b) Sporangiophores with sporangia (in situ). (c) Sporangiospores. (a, b) Scale bar = 50 μm; (c) scale bar = 5 μm.
Comparison of the main phenotypic characteristics of Saksenaea spp.
| Species | Growth at 37°C on CZA after 4 d (mm) | Growth at 42°C | Sporangiophore length ( | Shape of mature sporangia-venters | Spore size ( | Spore shape | References |
|---|---|---|---|---|---|---|---|
|
| 25–30 | − | 75–130 | Conical | 4.5–6 × 2.5–3 | Short cylindrical -capsulate | This study |
|
| >85 | + | 100–150 | Spherical | 5–5.5 × 2.5–3 | Ellipsoid-biconcave | [ |
|
| >85 | + | 50–75 | Spherical | 3.5–7 × 2–3.5 | Long cylindrical | [ |
|
| >85 | − | 80–100 | Spherical | 5–6.5 × 3–4.5 | Oblong | [ |
|
| 35–40 | − | 150–230 | Spherical | 5.5–8 × 3.5–4 | Trapezoid | [ |
|
| >85 | + | 65–100 | Spherical | 5–7 × 2–3 | Long cylindrical | [ |
Filling the Petri dish (diameter, 9 cm); shape of sporangia listed are based on available drawings and illustrations in the referred studies.
Figure 5In vitro antifungal susceptibility of Saksenaea dorisiae BiMM-F232 towards selected antifungals after 3 days incubation at 37°C. MIC Test strips: (a) posaconazole (POS), (b) itraconazole (ITC), (c) ketoconazole (KE), (d) caspofungin (CAS), (e) flucytosine (FC),(f) fluconazole (FLU), (g) voriconazole (VO), (h) amphotericin B (AMB), and (i) antifungal discs(left top to left bottom: ketoconazole KCA 15 μg and itraconazole ITC 8 and 15 μg; right top to right bottom: clotrimazole CLO 50 μm and fluconazole FLU 25 and 100 μm); all plates were overgrown by the fungus after prolonged incubation (5 days) at 37°C.
In vitro antifungal susceptibility of Saksenaea dorisiae (BiMM-F232) towards 15 antifungal discs after 3 days of incubation at 37°C.
| Antimycotic | Antifungal disc (concentration | Spores resistant/sensitive (mm zone) | Mycelial pellets resistant/sensitive (mm zone) |
|---|---|---|---|
| Amphotericin B | 20 | R/S (9) | R |
| Caspofungin | 5 | R | R |
| Ciclopirox | 50 | S (25) | R |
| Flucytosine | 1 | R | R |
| Griseofulvin | 10 | R | R |
| Nystatin | 100 IU | R/S (6) | R |
| Terbinafine | 30 | S (25) | S (30) |
| Clotrimazole | 50 | S (25) | R |
| Econazole | 10 | S (15) | R |
| Fluconazole | 100 | R | R |
| Itraconazole | 8 | S (15) | R |
| Ketoconazole | 15 | R/S (8) | R |
| Miconazole | 10 | R/S (4) | R |
| Posaconazole | 5 | S (15) | R |
| Voriconazole | 1 | R | R |
R = -resistant; S = sensitive. Responses with an asterisk indicate re-growing of the fungus into the inhibition zones after prolonged incubation (5 days at 37°C); spores (4.0 × 105 CFU/mL) and mycelial pellets in size of 50–200 μm in diameter (2.0 × 104/mL).